X4 Pharmaceuticals (XFOR) FCF Margin (2018 - 2025)
X4 Pharmaceuticals (XFOR) posted FCF Margin of 604.28% for Q4 2025, up 61.63% on a QoQ basis from 1575.07% in Q3 2025, and up 169948.0% year-over-year from N/an in Q4 2024.
X4 Pharmaceuticals (XFOR) FCF Margin (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals' FCF Margin history runs 4 years deep, the most recent figure standing at 604.28% for Q4 2025.
- Quarterly FCF Margin rose 169948.0% year-over-year to 604.28% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 243.84% (up 620317.0% YoY) and the FY2025 annual result came in at 243.84%, up 488823.0% from the prior year.
- FCF Margin was 604.28% for Q4 2025 at X4 Pharmaceuticals, up from 1575.07% in the prior quarter.
- Across five years, FCF Margin topped out at 42.93% in Q1 2025 and bottomed at 11373.71% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | -604.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -604.28% |
| Sep 30, 2025 | -1,575.07% |
| Jun 30, 2025 | -1,517.08% |
| Mar 31, 2025 | -42.93% |
| Dec 31, 2024 | -2,303.77% |
| Sep 30, 2024 | -6,093.57% |
| Jun 30, 2024 | -11,373.71% |
| Mar 31, 2020 | -536.07% |
| Dec 31, 2018 | -192.40% |